Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer

Abstract

Declaration of financial/other relationshipsCRPdV, EC and MDA are employees of MSD Brazil, São Paulo, Brazil. LCH was an employee of MSD Brazil, São Paulo, Brazil, at the time this research was conducted. LP and CSB received honoraria from MSD Brazil to provide scientific consultancy for the study design and data analysis. Author ContributionsLP and CSB contributed to conception, design or planning of the study, analysis of the data, interpretation of the results, drafting the manuscript and critically reviewing or revising it for important intellectual content. MDA and EC contributed to conception, design or planning of the study, analysis of the data, interpretation of the results and critically reviewing or revising the manuscript for important intellectual content. CRPdV and LCH contributed to analysis and acquisition of the data, interpretation of the results, drafting the manuscript and critically reviewing or revising it for important intellectual content. JME peer reviewers on this manuscript have received an honorarium from JME for their review work, but have no other relevant financial relationships to disclose.